---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001515"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:02:30.875185+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics reports FY2023 net loss of $42.5M; CTX-009 data expected by end 2024

## Summary
- Net loss $42.5M ($0.33/share) vs $39.2M loss in 2022; R&D expenses rose 27% to $38.1M.
- Cash and marketable securities $152.5M at Dec 31, 2023; runway into mid-2026.
- CTX-009 Phase 2/3 BTC study (COMPANION-002) enrollment ongoing; top-line data expected year-end 2024.
- CTX-009 Phase 2 CRC study (COMPANION-003) Stage 1 enrollment complete; top-line data mid-2024.
- CTX-471 Phase 2 monotherapy planning underway for melanoma with novel biomarker; combination arm with KEYTRUDA enrolling.

## SEC filing metadata
- accession: 0001171843-24-001515
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184324001515/0001171843-24-001515-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184324001515/f8k_032024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001515
- JSON: https://secwatch.observer/filing/0001171843-24-001515.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001515.txt

## Key facts
- Earnings Releases
  Compass Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $42.5 million or $0.33 per common share, EPS $0.33 per common share.
  - Period: the year ended December 31, 2023
  - Net income: Net loss for the year ended December 31, 2023, was $42.5 million or $0.33 per common share
  - EPS: $0.33 per common share
  - Result: reported results
  source text: On March 21, 2024, Compass Therapeutics, Inc. issued a press release announcing financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184324001515/0001171843-24-001515-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.